Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk

Abstract We aimed to compare the (1) clinical outcomes including composite cardiovascular outcomes, cardiovascular death, and all-cause death, and (2) healthcare costs of using liraglutide and basal insulin as an initial treatment for patients with type 2 diabetes mellitus (T2DM) and high cardiovasc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wan-Chun Huang, Yen-Chou Chen, Chung-Hsuen Wu, Yu Ko
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6429c9ea537d444484a6b4cbeca3e3a2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6429c9ea537d444484a6b4cbeca3e3a2
record_format	dspace
spelling	oai:doaj.org-article:6429c9ea537d444484a6b4cbeca3e3a22021-12-02T15:23:00ZCardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk10.1038/s41598-020-80753-92045-2322https://doaj.org/article/6429c9ea537d444484a6b4cbeca3e3a22021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-80753-9https://doaj.org/toc/2045-2322Abstract We aimed to compare the (1) clinical outcomes including composite cardiovascular outcomes, cardiovascular death, and all-cause death, and (2) healthcare costs of using liraglutide and basal insulin as an initial treatment for patients with type 2 diabetes mellitus (T2DM) and high cardiovascular diseases (CVD) risk. This is a retrospective cohort study using Taiwan’s Health and Welfare Database. A total of 1057 patients treated with liraglutide were identified and matched with 4600 patients treated with basal insulin. The liraglutide group had a lower risk of a composite CVD outcome (hazard ratio (HR) 0.65; 95% confidence interval (CI) 0.50–0.85; p < 0.01), all-cause mortality (HR 0.40; 95% CI 0.28–0.59; p < 0.0001), and nonfatal stroke (HR 0.54; 95% CI 0.34–0.87; p = 0.01). Compared to the basal insulin group, the liraglutide group had lower median per-patient-per-month (PPPM) inpatient, emergency room (ER), and total medical costs, but higher median PPPM outpatient, total pharmacy, and total costs (all p < 0.0001). In conclusion, compared to basal insulin, liraglutide was found to be associated with reduced risk of a composite CVD outcome, nonfatal stroke, and all-cause mortality among high CVD risk patients with T2DM. In addition, liraglutide users had lower inpatient, ER, and total medical costs, but they had higher outpatient and total pharmacy costs.Wan-Chun HuangYen-Chou ChenChung-Hsuen WuYu KoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Wan-Chun Huang Yen-Chou Chen Chung-Hsuen Wu Yu Ko Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk
description	Abstract We aimed to compare the (1) clinical outcomes including composite cardiovascular outcomes, cardiovascular death, and all-cause death, and (2) healthcare costs of using liraglutide and basal insulin as an initial treatment for patients with type 2 diabetes mellitus (T2DM) and high cardiovascular diseases (CVD) risk. This is a retrospective cohort study using Taiwan’s Health and Welfare Database. A total of 1057 patients treated with liraglutide were identified and matched with 4600 patients treated with basal insulin. The liraglutide group had a lower risk of a composite CVD outcome (hazard ratio (HR) 0.65; 95% confidence interval (CI) 0.50–0.85; p < 0.01), all-cause mortality (HR 0.40; 95% CI 0.28–0.59; p < 0.0001), and nonfatal stroke (HR 0.54; 95% CI 0.34–0.87; p = 0.01). Compared to the basal insulin group, the liraglutide group had lower median per-patient-per-month (PPPM) inpatient, emergency room (ER), and total medical costs, but higher median PPPM outpatient, total pharmacy, and total costs (all p < 0.0001). In conclusion, compared to basal insulin, liraglutide was found to be associated with reduced risk of a composite CVD outcome, nonfatal stroke, and all-cause mortality among high CVD risk patients with T2DM. In addition, liraglutide users had lower inpatient, ER, and total medical costs, but they had higher outpatient and total pharmacy costs.
format	article
author	Wan-Chun Huang Yen-Chou Chen Chung-Hsuen Wu Yu Ko
author_facet	Wan-Chun Huang Yen-Chou Chen Chung-Hsuen Wu Yu Ko
author_sort	Wan-Chun Huang
title	Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk
title_short	Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk
title_full	Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk
title_fullStr	Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk
title_full_unstemmed	Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk
title_sort	cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/6429c9ea537d444484a6b4cbeca3e3a2
work_keys_str_mv	AT wanchunhuang cardiovascularoutcomesandhealthcarecostsofliraglutideversusbasalinsulinfortype2diabetespatientsathighcardiovascularrisk AT yenchouchen cardiovascularoutcomesandhealthcarecostsofliraglutideversusbasalinsulinfortype2diabetespatientsathighcardiovascularrisk AT chunghsuenwu cardiovascularoutcomesandhealthcarecostsofliraglutideversusbasalinsulinfortype2diabetespatientsathighcardiovascularrisk AT yuko cardiovascularoutcomesandhealthcarecostsofliraglutideversusbasalinsulinfortype2diabetespatientsathighcardiovascularrisk
_version_	1718387329128726528

Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk

Ejemplares similares